Sign In
Buy AXSM
$228.28
-5.52 (-2.36%)
At Close: Jul 13, 2026
3 Under-the-Radar Stocks to Buy and Hold
02:30pm, Friday, 10'th Jul 2026
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Better Growth Buy: Axsome vs Revolution Medicines
03:55am, Thursday, 09'th Jul 2026
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
Axsome Begins Phase III Study on Solriamfetol for ADHD in Children
12:20pm, Wednesday, 08'th Jul 2026
AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07:00am, Tuesday, 07'th Jul 2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
06:10pm, Monday, 06'th Jul 2026
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.
08:05am, Thursday, 02'nd Jul 2026
Axsome specializes in central nervous system disorders, including depression, migraine, and fibromyalgia. Axsome's Auvelity recently won approval to treat agitation associated with Alzheimer's disease
Why Axsome Stock Has Doubled In Nine Months
12:10pm, Wednesday, 01'st Jul 2026
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inb
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
07:00am, Thursday, 18'th Jun 2026
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
3 Under-the-Radar Stocks to Buy and Hold for a Decade
03:30am, Tuesday, 16'th Jun 2026
All three could become highly prominent biotech companies within 10 years.
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
07:00am, Monday, 15'th Jun 2026
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:58pm, Monday, 08'th Jun 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline
12:02am, Saturday, 06'th Jun 2026
Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing to launch Auvelity in Alzheimer's disease agitation this month while continuing to expand the drug's use in major depressive d
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
07:00am, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?
12:30pm, Wednesday, 03'rd Jun 2026
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
